Ana-Iris Schiefer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8883153/publications.pdf

Version: 2024-02-01

430874 434195 1,054 50 18 31 citations h-index g-index papers 51 51 51 2063 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood, 2018, 132, 694-706.	1.4	132
2	PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas. Nature Medicine, 2012, 18, 1699-1704.	30.7	113
3	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discovery, 2022, 12, 372-387.	9.4	77
4	Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nature Communications, 2016, 7, 10087.	12.8	65
5	Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice. Nature Genetics, 2021, 53, 500-510.	21.4	56
6	Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling. Cell Reports, 2016, 17, 596-608.	6.4	55
7	Oncogenic role of <scp>miR</scp> â€155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. Journal of Pathology, 2015, 236, 445-456.	4.5	49
8	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood, 2018, 132, 2389-2400.	1.4	45
9	Expression of RAGE and HMGB1 in Thymic Epithelial Tumors, Thymic Hyperplasia and Regular Thymic Morphology. PLoS ONE, 2014, 9, e94118.	2.5	30
10	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica, 2020, 105, 435-447.	3. 5	27
11	Lymphovascular invasion of tumor cells in lymph node metastases has a negative impact on survival in esophageal cancer. Surgery, 2016, 160, 331-340.	1.9	26
12	Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2016, 18, 370-377.	2.8	25
13	Genomic Spectrum and Phenotypic Heterogeneity of Human IL-21 Receptor Deficiency. Journal of Clinical Immunology, 2021, 41, 1272-1290.	3.8	25
14	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs $t(8;21)$. Blood Advances, 2021, 5, 2481-2489.	5.2	25
15	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. Medicine (United States), 2015, 94, e2388.	1.0	24
16	CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis. Blood, 2017, 129, 371-382.	1.4	24
17	Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 1831-1838.	1.3	23
18	Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH. PLoS ONE, 2014, 9, e106440.	2.5	23

#	Article	IF	CITATIONS
19	Impact of white blood cell counts at diagnosis and during followâ€up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. British Journal of Haematology, 2017, 179, 166-169.	2.5	18
20	Coreâ€binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I―CBF) Tj I	ETQ <u>q</u> 0 0 0) rgBT /Overloo
21	Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome. Oncotarget, 2018, 9, 21861-21875.	1.8	17
22	Transformed mucosaâ€associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reactionâ€based clonality analysis. British Journal of Haematology, 2019, 186, 448-459.	2.5	16
23	PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. Pathology and Oncology Research, 2020, 26, 2225-2235.	1.9	15
24	PDâ€L1 and PD1 expression in postâ€transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An interâ€and intraâ€individual descriptive study covering the whole spectrum of PTLD categories. Cancer Medicine, 2019, 8, 4656-4668.	2.8	14
25	Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells. Blood, 2019, 133, 2597-2609.	1.4	14
26	Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. Leukemia and Lymphoma, 2016, 57, 206-208.	1.3	12
27	Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors. Scientific Reports, 2019, 9, 17359.	3.3	12
28	Extranodal marginal zone lymphoma of the CNS arising after a long-standing history of atypical white matter disease. Leukemia Research, 2012, 36, e155-e157.	0.8	10
29	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals <scp>cM</scp> et as a negative prognostic factor. Histopathology, 2015, 67, 799-805.	2.9	10
30	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers, 2021, 13, 5592.	3.7	9
31	Clinical prognostic scores for patients with thymic epithelial tumors. Scientific Reports, 2019, 9, 18581.	3.3	6
32	Heat shock protein $90\hat{l}_{\pm}$ in thymic epithelial tumors and non-thymomatous myasthenia gravis. Oncolmmunology, 2020, 9, 1756130.	4.6	6
33	Coreâ€binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology, 2021, 43, e19-e25.	1.3	6
34	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. Oncotarget, 2016, 7, 12191-12205.	1.8	6
35	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. Advances in Medical Sciences, 2022, 67, 154-162.	2.1	4
36	Tumor cell budding in preoperative biopsies of esophageal and gastroesophageal junction carcinoma independently predicts survival in a grade-dependent manner. Surgery, 2022, 172, 567-574.	1.9	4

#	Article	IF	CITATIONS
37	Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis. Cancers, 2020, 12, 2291.	3.7	3
38	Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome. British Journal of Cancer, 2022, 127, 1162-1171.	6.4	3
39	Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project. Blood, 2016, 128, 4252-4252.	1.4	2
40	BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL. Cancers, 2022, 14, 151.	3.7	2
41	Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody. Memo - Magazine of European Medical Oncology, 2013, 6, 123-126.	0.5	1
42	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	1.4	1
43	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. Blood, 2019, 134, 4037-4037.	1.4	1
44	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia, 2021, 23, 1183-1191.	5.3	1
45	Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemiaâ€"microenvironment-dependent lineage differentiation derived from a common progenitor?. Journal of Hematopathology, 2021, 14, 325-332.	0.4	0
46	A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features Blood, 2012, 120, 2685-2685.	1.4	0
47	High Expression of AF1q Is an Adverse Prognostic Factor in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation. Blood, 2015, 126, 5321-5321.	1.4	0
48	Clinical Impact of Bone Marrow Morphology for the Diagnosis of Essential Thrombocythemia: Comparison Between the British Standards (BCSH) and the WHO Criteria. Blood, 2015, 126, 2816-2816.	1.4	0
49	Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis. Blood, 2016, 128, 1932-1932.	1.4	0
50	CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. Cancers, 2022, 14, 3070.	3.7	0